Quantcast

Bristol Myers Squibb to demolish penicillin facilities

The East Syracuse campus of Bristol Myers Squibb is evolving.

Almost half of its total square footage will soon be demolished as part of a site transformation project. Phase 1 involves the demolition of existing buildings, creation of green space and some renovations.

According to BMS, the two-phase project will take the campus from its former role as a penicillin-producing facility to a center for technology, research and development, launching early stage medicines.

The facility stopped manufacturing penicillin in 2006 and those buildings have since been idle. The Food and Drug Administration has strict policies about penicillin, said Pam Brunet, BMS community affairs manager, and the buildings cannot be re-used due to residual contamination and the possibility of allergic reactions.

Brunet said no new buildings need to be constructed at this time as the company has made major investments in its biologics drug development and manufacturing facilities on the southern end of campus. Employees will transfer to those already renovated buildings that include office, laboratory and warehouse space.

The project will reduce energy consumption and operating costs. Green elements of the project include recycling and re-use of materials.

"We'll look less industrial and more like a bio-tech campus," Brunet said. "[This change] is pretty consistent with other facilities around the world. BMS is evolving to become a bio-farm company; our work is now bio-technology related."

Phase 1 is expected to be completed by 2013. Additional demolition is expected to take place during Phase 2.

0
Vote on this Story by clicking on the Icon

Comments

Use the comment form below to begin a discussion about this content.

Sign in to comment